~~<i id='9D6AE88A66'><strike id='9D6AE88A66'><tt id='9D6AE88A66'><pre id='9D6AE88A66'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

hotspot

author：comprehensive 2025-09-27 23:32:25 - browse：7384

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： White House drug shortages task force keeps mum with Congress

entertainment

knowledge

entertainment

hotspot

explore

RubyWallauforSTATBiogen,theiconicbutembattledbiotechfirm,isshutteringBiogenDigitalHealth,itsroughly1

WSS

Listen: Who gets the credit for GLP

Did you have Obamacare on your GOP debate bingo card?

Cigna to pay $172 million to settle Medicare Advantage fraud probe

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

TB outbreak tied to bone grafts underscores testing shortcomings

Medicaid, Medicare dual

leisure time

hotspot

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Sudafed saga points to U.S. issues with evaluating older drugs

Dobbs anniversary: the lost opportunity of abortion as health care

Maui funeral service workers on devastation of fires: 'I'm in shock'

At least 13 dead in Texas as scorching temps continue

Covid vaccines: Private market messier than government rollout

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Listen: Your guide to Wegovy's blockbuster heart study

Walensky prepares to leave CDC — and Congress — behind

The history of OxyContin, told through Purdue Pharma documents

knowledge

Address the ethical violations that led to 'Three Identical Strangers'

Who are the detained American citizens released from prison in Iran?

Intercept Pharmaceuticals sells itself for less than $1 billion

Some of the ways extreme heat will change life as we know it

Listen: Your guide to Wegovy's blockbuster heart study

The history of OxyContin, told through Purdue Pharma documents

entertainment

hotspot

explore

explore